Gilead Sciences ( (GILD) ) has risen by 8.82%. Read on to learn why.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gilead Sciences’ share price climbed 8.82% over the past week, buoyed by a wave of supportive analyst commentary across Wall Street. Despite one Hold rating from RBC Capital, which set a $103 price target when the stock was trading at $129.11, the broader sentiment around the biotech heavyweight has remained notably upbeat. Investors appear to be focusing less on isolated cautious calls and more on the strengthening consensus that Gilead’s long‑term pipeline and earnings profile remain attractive within the healthcare sector.
Much of the momentum has been driven by a series of reiterated or maintained Buy ratings from major banks and research houses. TD Cowen reaffirmed its positive stance with a $125 price target when Gilead shares were at $121.26, highlighting confidence in the company’s fundamentals and growth prospects. J.P. Morgan likewise reiterated a Buy rating as the stock traded around the low $120s, signaling continued institutional support and helping underpin the recent move higher.
Crucially for traders and longer-term investors alike, Gilead Sciences currently carries a Strong Buy consensus from analysts, with average target prices clustered around the mid‑$130s, implying further upside from recent levels. Additional Buy affirmations from firms such as Scotiabank, with targets as high as $140, have reinforced the perception that Gilead remains undervalued relative to its prospects. This combination of broad-based bullish research coverage and visible target-price headroom has been a key catalyst behind the stock’s 8.82% advance over the last week.